# Western US Expansion Playbook: Cloud Assurance ‚Üí AI Expansion
## Account Growth Report - LIVE DATA VERSION

**Generated**: February 3, 2026  
**Data Sources**: Finance MCP, Labor MCP, Sales MCP (live)

---

## 1) Executive Summary

| Metric | Value | Source |
|--------|-------|--------|
| **Region** | Western US | ‚Äî |
| **Total CA accounts in region** | 16 identified | Finance MCP (LTV) |
| **CA ARR / TCV under contract** | ~$310K LTV (Western biotechs) | Finance MCP |
| **Expansion target (12 mo)** | $1.5M (AI + adjacent) | Target |
| **Team capacity** | 83% util (118% overloaded) | Labor MCP |
| **At-risk deals** | 52 | Sales MCP |

### Primary Expansion Motions
1. **AI Enablement** ‚Äî Regulated content + workflow (Box/Veeva customers)
2. **GenAI Governance** ‚Äî Vendor assessment / TPRM for AI tools
3. **Data Strategy** ‚Äî Analytics foundation for AI readiness
4. **Managed Services Consolidation** ‚Äî One team, one SOW

### Top 10 Priority Accounts (Tier 1)
Based on LTV, growth trajectory, and expansion signals:

| Rank | Account | LTV | YoY Growth | GP% | Expansion Signal |
|------|---------|-----|------------|-----|------------------|
| 1 | **National Resilience** | $6.7K | N/A | 100% | üéØ $825M funding, 2000+ employees, TINY footprint |
| 2 | **Kyverna Therapeutics** | $23.0K | +175.6% | 99.6% | üî• Exploding growth, CAR-T manufacturing |
| 3 | **Neumora Therapeutics** | $51.6K | +26.2% | 95.9% | Healthy, neuro pipeline expanding |
| 4 | **Maze Therapeutics** | $49.5K | -62.2% | 78.3% | ‚ö†Ô∏è Declining - intervention needed |
| 5 | **Caribou Biosciences** | $35.0K | +59.3% | 72.5% | CRISPR scale-up, manufacturing needs |
| 6 | **VIR Biotechnology** | $34.1K | -61.9% | 95.7% | ‚ö†Ô∏è Declining - win back |
| 7 | **Gilead Sciences** | $2.13M | ‚Äî | 22% | ‚ö†Ô∏è MARGIN FIX - convert to managed |
| 8 | **Kite Pharma** | $2.08M | ‚Äî | 20% | ‚ö†Ô∏è MARGIN FIX - CAR-T AI governance |
| 9 | **Amgen** | $1.75M | ‚Äî | 21% | ‚ö†Ô∏è MARGIN FIX - consolidate SOWs |
| 10 | **Protagonist Therapeutics** | $20.9K | +32.4% | 93.0% | Healthy, cross-sell AI governance |

---

## 2) What Cloud Assurance Actually Buys You (the wedge)

**Permission to expand message:**
- CA already includes end-to-end compliance upkeep with releases, automated testing, and always-on transparency
- Customers with fragmented subscriptions and SOWs are ripe for consolidation
- Clear path for expansion into AI in regulated systems

**Western Region CA Wedge Opportunities:**
| Account Type | Count | Expansion Play |
|--------------|-------|----------------|
| High GP (>80%) + Growing | 6 | AI Enablement, expand services |
| High GP (>80%) + Declining | 2 | Win-back + AI governance |
| Low GP (<40%) + Large | 4 | Managed services consolidation |
| Small footprint + Large company | 2 | Massive land & expand |

---

## 3) Tiering (Based on MCP Data)

### Tier 1 ‚Äî Deep Research (10 accounts)
**Criteria**: LTV > $20K OR strategic expansion signal OR margin fix opportunity

| Account | LTV | Trigger | Play |
|---------|-----|---------|------|
| National Resilience | $6.7K | $825M funding, CDMO leader | Land & Expand |
| Kyverna | $23K | 175% growth | AI Enablement |
| Neumora | $51.6K | Healthy, neuro AI | AI Governance |
| Maze | $49.5K | -62% decline | Win-back + consolidate |
| Caribou | $35K | 59% growth | Manufacturing + AI |
| VIR Bio | $34.1K | -62% decline | Win-back |
| Gilead | $2.13M | 22% GP | Managed services |
| Kite | $2.08M | 20% GP | CAR-T AI governance |
| Amgen | $1.75M | 21% GP | SOW consolidation |
| Protagonist | $20.9K | 32% growth | Cross-sell AI |

### Tier 2 ‚Äî Medium Research (6 accounts)
| Account | LTV | Status |
|---------|-----|--------|
| Numerion Labs (ex-Atomwise) | $15K | Churned - re-engage |
| Ultragenyx | $11.7K | Churned - re-engage |
| Guardant Health | $8.2K | Dormant |
| Neurocrine | $890K | Existing - expand |
| Enovis | $773K | Margin fix (18% GP) |
| Genentech | $1.8M | Strategic - protect |

### Tier 3 ‚Äî Light Research (New Logos)
68 Western targets not yet customers - prioritize by:
- Funding (>$100M)
- Cell therapy / AI focus
- Hiring signals

**Top New Logo Targets:**
1. Cellares ($257M, BMS deal)
2. Insitro ($400M+, Daphne Koller)
3. Freenome (IPO, Roche partnership)
4. Tune Therapeutics ($175M, new CEO)
5. 64x Bio ($55M, AAV manufacturing)

---

## 4) Expansion Plays Mapped to Western Accounts

### Play 1 ‚Äî AI Enablement in Regulated Content + Workflows

**Best fit accounts:**
| Account | Why | Use Case | Expected Value |
|---------|-----|----------|----------------|
| Kyverna | CAR-T manufacturing docs | Doc classification, batch records | $75-150K |
| Caribou | CRISPR protocols | Error detection, version control | $50-100K |
| Neumora | Clinical trial docs | Content summarization | $40-80K |
| National Resilience | CDMO quality docs | Automated extraction | $200-400K |

### Play 2 ‚Äî AI Governance + Vendor Assessment / TPRM

**Best fit accounts:**
| Account | Why | Trigger | Expected Value |
|---------|-----|---------|----------------|
| Kite Pharma | CAR-T + Gilead AI initiatives | AI tool proliferation | $100-200K |
| Gilead | Enterprise AI governance | Multi-division alignment | $150-300K |
| Maze | AI drug discovery platform | Governance gap | $50-100K |
| Insitro (new) | ML-first company | Regulatory readiness | $75-150K |

### Play 3 ‚Äî Foundation for Analytics and AI

**Best fit accounts:**
| Account | Why | State | Expected Value |
|---------|-----|-------|----------------|
| Amgen | Legacy data silos | Data not AI-ready | $200-400K |
| National Resilience | Manufacturing data | Scaling CDMO ops | $150-300K |
| Guardant | Diagnostics data | Dormant relationship | $75-150K |

### Play 4 ‚Äî Managed Services Consolidation

**Best fit accounts (fragmented SOWs at low GP):**
| Account | Current GP | Target GP | Revenue Impact |
|---------|------------|-----------|----------------|
| Gilead | 22% | 50%+ | +$600K margin |
| Kite | 20% | 50%+ | +$625K margin |
| Amgen | 21% | 50%+ | +$510K margin |
| Enovis | 18% | 50%+ | +$250K margin |
| **TOTAL** | ‚Äî | ‚Äî | **+$1.98M margin** |

---

## 5) Delivery Capacity Check (Labor MCP)

| Metric | Value | Status |
|--------|-------|--------|
| Delivery resources | 680 | ‚Äî |
| Avg utilization | 83.3% | ‚úÖ Normal |
| Overloaded resources | 39 (118% avg) | üî¥ Stressed |
| Optimal capacity | 11 | ‚Äî |
| Underutilized | 0 | ‚Äî |

**Capacity Constraint Analysis:**
- Current team running HOT (39 overloaded)
- Can NOT take on major new implementations without hiring
- Managed services plays are BETTER (steady-state, not spike)
- Need 3-5 new hires for Seattle expansion

**Recommended Hiring:**
| Role | Location | For Play |
|------|----------|----------|
| Account Director | Seattle/PNW | Seattle market entry |
| AI Solutions Architect | SF Bay | AI Enablement |
| Delivery Lead | San Diego | Resilience expansion |
| Managed Services Lead | LA | Consolidation plays |

---

## 6) Account-by-Account Reports

### TIER 1 ACCOUNT: National Resilience

#### 6.1 Account Profile
- **Account name:** National Resilience, Inc.
- **HQ / West footprint:** San Diego (HQ), multiple US sites
- **Industry segment:** Biomanufacturing CDMO
- **Current LTV:** $6,695 (TINY for this company!)
- **Current GP:** 100%
- **Employees:** 2,000+
- **Funding:** $825M (Oct 2025)

#### 6.2 Current State
- Systems in scope: Unknown (minimal engagement)
- Release cadence: Unknown
- Pain points: Unknown (no ticket data)
- Compliance themes: CDMO = heavy GxP burden

#### 6.3 Expansion Triggers ("Why now")
- **Internal:** Minimal USDM footprint despite massive company
- **External:** $825M funding Oct 2025, new CEO Dec 2024, major expansion
- **Budget timing:** Post-funding = budget available

#### 6.4 Buyer Map
- **Executive sponsor:** TBD (new CEO Dec 2024)
- **Quality/Compliance:** TBD
- **IT owner:** TBD
- **Research needed:** Build relationship map

#### 6.5 Expansion Hypothesis
- **Best next play:** Foundation for Analytics + AI (manufacturing data)
- **Why it fits:** CDMO at scale needs data infrastructure for AI quality
- **Expected value:** $200-400K initial, $1M+ potential
- **Delivery model:** Managed services
- **Proof needed:** Discovery workshop to assess current state

#### 6.6 Next 30/60/90 Day Plan
- **30 days:** Exec intro meeting, map stakeholders, validate trigger
- **60 days:** Discovery workshop scoped + priced
- **90 days:** SOW signed for Phase 1 OR clear no-go

#### 6.7 Exit Criteria
- **GO if:** Executive priority confirmed, budget window identified, sponsor engaged
- **NO-GO if:** No access to buyers, no measurable outcome, can't staff

---

### TIER 1 ACCOUNT: Kyverna Therapeutics

#### 6.1 Account Profile
- **Account name:** Kyverna Therapeutics Inc
- **HQ / West footprint:** Emeryville, CA (Bay Area)
- **Industry segment:** Autoimmune CAR-T therapy
- **Current LTV:** $23,000
- **YoY Growth:** +175.6% üî•
- **Current GP:** 99.6%
- **Employees:** 100+
- **Stage:** Clinical (Phase 1/2)

#### 6.2 Current State
- 2025 revenue: $16.9K (up from $6.1K in 2024)
- Excellent margin (99.6% GP)
- Growing rapidly
- First-mover in autoimmune cell therapy

#### 6.3 Expansion Triggers
- **Internal:** Rapid growth, manufacturing scale-up coming
- **External:** New CFO Jun 2025, clinical advancement
- **Budget timing:** Now (growth phase)

#### 6.4 Buyer Map
- **New CFO:** Key relationship to build
- **Quality:** Cell therapy = heavy validation needs

#### 6.5 Expansion Hypothesis
- **Best next play:** AI Enablement (CAR-T manufacturing docs)
- **Why it fits:** Scaling manufacturing = doc explosion
- **Expected value:** $75-150K
- **Delivery model:** Project ‚Üí Managed services
- **Proof needed:** Workshop on manufacturing readiness

#### 6.6 Next 30/60/90 Day Plan
- **30 days:** QBR with current champion, intro to CFO
- **60 days:** Manufacturing AI workshop
- **90 days:** Expansion SOW signed

---

### TIER 1 ACCOUNT: Gilead Sciences (Margin Fix)

#### 6.1 Account Profile
- **Account name:** Gilead Sciences
- **HQ / West footprint:** Oceanside (San Diego region)
- **Industry segment:** Antivirals, Oncology
- **Current revenue:** $2.13M
- **Current GP:** 22% ‚ö†Ô∏è (should be 50%+)

#### 6.2 Current State
- Large revenue but LOW margin
- Likely fragmented SOWs, T&M heavy
- Owns Kite Pharma (also low margin)

#### 6.3 Expansion Triggers
- **Internal:** Margin improvement opportunity
- **External:** AI initiatives across enterprise
- **Budget timing:** Enterprise, always budgeting

#### 6.5 Expansion Hypothesis
- **Best next play:** Managed Services Consolidation + AI Governance
- **Why it fits:** Consolidate fragmented SOWs, convert T&M to managed
- **Expected value:** +$600K margin improvement
- **Delivery model:** Multi-year managed services
- **Proof needed:** Current state assessment, quantify fragmentation

#### 6.6 Next 30/60/90 Day Plan
- **30 days:** Internal analysis of all Gilead SOWs
- **60 days:** Consolidation proposal with ROI model
- **90 days:** Executive presentation, MSA negotiation

---

## 7) Region-Level Dashboard

### Weekly Tracking Metrics

| Metric | Current | Target | Status |
|--------|---------|--------|--------|
| Tier 1 accounts researched | 3/10 | 10/10 | üü° In progress |
| Exec meetings booked | 0 | 5 | üî¥ Start |
| Workshops proposed | 0 | 3 | üî¥ Start |
| Pipeline created (CA expansion) | $0 | $500K | üî¥ Start |
| Win rate | 35.6% | 42% | ‚ö†Ô∏è Below target |
| Renewal risk (CA) | 2 (Maze, VIR) | 0 | ‚ö†Ô∏è Action needed |
| Delivery capacity | 39 overloaded | <20 | üî¥ Hire |

### Churn Signals (Sales MCP)
| Flag Type | Count | Action |
|-----------|-------|--------|
| SameDayFlip | 40 | Pipeline hygiene |
| Regression | 8 | Stage review |
| ResurrectedFromLost | 4 | Zombie deals |

---

## 8) Report Deliverables Status

### Minimum Viable (2 weeks) ‚Äî IN PROGRESS
- [x] Tiering complete for all CA accounts
- [x] Tier 1: Identified top 10
- [ ] Tier 1: 1-page reports for top 10 (3 done, 7 to go)
- [ ] Pipeline targets defined
- [ ] Named pursuits for top 10

### Full (6‚Äì8 weeks)
- [ ] All Tier 1 complete
- [ ] Tier 2 started
- [ ] Repeatable playbooks packaged
- [ ] Partner alignment plan

---

## 9) Key Actions This Week

1. **Complete Tier 1 account profiles** (7 remaining)
2. **Schedule QBR with Kyverna** (growth account)
3. **Internal Gilead SOW audit** (quantify fragmentation)
4. **National Resilience intro** (exec outreach)
5. **Win-back campaign** for Maze & VIR
6. **Hiring req** for Seattle Account Director

---

*Live data from Finance MCP (port 3003), Labor MCP (port 3002), Sales MCP (port 3001)*
*Generated by Magentic - February 3, 2026*
